Vaishali Pharma share price & results
- Jun 2026
- Jul 2026
Mumbai-based pharma trading and marketing company for APIs, formulations, surgical, veterinary, nutraceutical and oncology products across 40+ export countries
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 22.9 | −3.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 6.5 | +0.7 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 1.5 | +16.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 6.48 | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. | |
| Free cash flow margin | Fiscal year | FY ending Mar 2026 | Not in the analysed materials. No older figure is substituted. | ||
| Revenue growth (YoY) | Trailing twelve months | TTM to Jun 2026 | Not in the analysed materials. No older figure is substituted. |
Price
Performance −65.8% 1Y
1Y: ₹20.76 on 14 Oct 2024 → ₹7.1. High ₹20.76 (14 Oct 2024), low ₹5.98 (20 Mar 2026).
- Previous close
- ₹6.85
- Market cap
- ₹108 Cr
- 52-week range
- ₹5.98 – ₹9.02
- Price to earnings (TTM to Jun 2026)
- 24.16×
- Return on equity (TTM to Jun 2026)
- 6.48%
Overview
- Symbol
- NSE:VAISHALI
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Vaishali Pharma Limited does
Based on the company's own presentations, annual report and earnings calls.
Vaishali Pharma trades and markets Active Pharmaceutical Ingredients (APIs), pharmaceutical formulations, surgical products, veterinary supplements, herbal/nutraceutical products and oncology products for both human and animal health. It began in 1989 as an API trading company and expanded in 2012 into marketing formulations for a global clientele, now supplying domestic customers and exporting to international markets including Russia, D.R. Congo, Kenya and Vietnam. The company also manages domestic and international marketing operations for nutraceutical maker Sankalp Life Care under a strategic partnership, and supports its supply chain with a warehouse in Bhiwandi, Maharashtra.
Segments
- Active Pharmaceutical Ingredients (APIs)
- Pharmaceutical Formulations
- Surgical Products
- Veterinary Products
- Nutraceutical Products
- Oncology Products
- Export countries
- 40+
- Products (SKUs)
- 1,500+
- Brands
- 250+
- Customers
- 1,000+
- Locations (offices/warehouses)
- 35+
- Warehouse capacity (Bhiwandi, Maharashtra)
- 100+ tonnes
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 1 fiscal year held (Mar 2026 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +16% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 21 | 28 | 32 | 24 | 33 | 25 | 27 | 23 |
| Expenses | 18 | 27 | 38 | 22 | 32 | 23 | 27 | 21 |
| Operating profit | 2 | 1 | -6 | 1 | 1 | 2 | -0 | 1 |
| Operating margin | 11.6% | 4.9% | −18.7% | 5.8% | 4.2% | 6.3% | −0.7% | 6.5% |
| Other income | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 3 | 2 | -6 | 2 | 2 | 2 | 0 | 2 |
| Tax rate | 25.1% | 24.9% | −23.4% | 26.4% | 28.3% | 28.2% | −50.0% | 13.9% |
| Net profit | 2 | 1 | -4 | 1 | 1 | 1 | 0 | 1 |
| EPS (₹ per share) | 0.18 | 0.13 | -0.40 | 0.12 | 0.09 | 0.10 | 0.02 | 0.11 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 86 | 99 | 109 |
| Expenses | 85 | 99 | 105 |
| Operating profit | 1 | 0 | 4 |
| Other income | 2 | 3 | 4 |
| Interest | 2 | 2 | 2 |
| Depreciation | 1 | 0 | 1 |
| Profit before tax | 1 | 1 | 5 |
| Net profit | 1 | 1 | 4 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 11 | 11 | 11 | 11 | 26 | 26 |
| Reserves | 12 | 16 | 30 | 32 | 39 | 43 |
| Borrowings | 18 | 21 | 15 | 13 | 12 | 19 |
| Other liabilities | 46 | 34 | 24 | 24 | 33 | 35 |
| Total liabilities | 86 | 82 | 79 | 80 | 110 | 123 |
| Fixed assets | 1 | 1 | 2 | 2 | 2 | 2 |
| Capital work in progress | 0 | 0 | 1 | 1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 5 |
| Other assets | 84 | 80 | 76 | 77 | 107 | 116 |
| Total assets | 86 | 82 | 79 | 80 | 110 | 123 |
| Line item | Mar 2026 |
|---|---|
| Cash from operations | 0 |
| Cash from investing | -5 |
| Cash from financing | 5 |
| Net cash flow | 0 |
| Free cash flow | 0 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 453 | 282 | 281 | 209 | 172 | 170 |
| Inventory days | 5 | 4 | 20 | 2 | 20 | 13 |
| Days payable | 321 | 163 | 120 | 95 | 116 | 81 |
| Cash conversion cycle | 137 | 122 | 181 | 116 | 77 | 102 |
| Working capital days | 146 | 111 | 208 | 169 | 231 | 212 |
| Return on capital employed | 10.0% | 19.0% | 22.0% | 6.0% | 5.0% | 9.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Ownership
Who owns it
Public hold 69.46% as of Jul 2026.
- Promoters 30.54%
- Foreign institutions 0.00%
- Public 69.46%
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- newly disclosed 3.36% held
The same filing shows 6 holders trimming and 1 off the list — both are in the register beside this.
Who is on the register
Named in the Jul 2026 filing
Every holder of Vaishali Pharma Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 23.07% | −0.80 pp | |
| 6.17% | unchanged | |
| 5.04% | −0.17 pp | |
| 3.36% | newly disclosed | |
| 3.16% | −0.11 pp | |
| 1.68% | −0.06 pp | |
| 1.52% | −0.05 pp | |
| 1.48% | −0.05 pp | |
| 1.26% | unchanged | |
| 0.74% | unchanged | |
| 0.74% | unchanged | |
| 0.53% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Vaishali Pharma Limited
Free account: one company. Everything above stays public.
Write why you follow Vaishali Pharma Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
- KR
KREBSBIOKrebs Biochemicals and Industries Limited - PA
PARNAXLABParnax Lab Limited - BA
BALAXIBalaxi Pharmaceuticals Limited - AL
ALPAAlpa Laboratories Limited - MA
MAKERSLMakers Laboratories Ltd. - PH
PHARMAIDPharmaids Pharmaceuticals Ltd. - SO
SOTACSotac Pharmaceuticals Ltd - IN
INVICTAInvicta Diagnostic Ltd
Learn to analyse Vaishali Pharma Limited
Guides on how to read this kind of business and the numbers that matter.